chronic neurological disorders

GluR6 antagonist-1 inhibits the pY binding site of tyrosine kinase p56lck SH2 domain.

MRS4917 is a potent and selective orally active P2Y14 receptor (hP2Y14R) antagonist, with an IC50 of 2.88 nM and a Ki of 1.67 nM, demonstrating over 18,000-fold selectivity against P2Y6R (IC50= 54 μM). It effectively reverses established mechanical allodynia in a chronic sciatic nerve compression (CCI) mouse model without affecting thermoregulation when administered orally. MRS4917 is applicable for research in neurological disorders.

PAR2modulator-1 (Compound C781) is an antagonist of the protease-activated receptor 2 (PAR2). It specifically inhibits the PAR2-dependent MAPK signaling pathway with an IC50 value of 8.5 μM. PAR2modulator-1 can effectively block pain responses triggered by PAR2 agonists. This compound is useful for research in inflammation, immunology, and neurological disorders, including chronic pain and asthma.

MAGLi 432 is a potent, highly selective, non-covalent, reversible (MAGL) inhibitor that binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme), MAGLi 432 can be used to study neurological disorders such as chronic inflammation, multiple sclerosis, blood-brain barrier dysfunction, Alzheimer's disease and Parkinson's disease.

μ-Conotoxin SxIIIC, an irreversible NaV channel inhibitor, is derived from Conus striolatus and is useful in researching neurological disorders, including chronic pain [1].

MmTx2 toxin, extracted from the venom of the coral snake, serves as a modulator of the GABA A receptor, increasing its responsiveness to agonists. This property renders it a useful tool in researching neurological disorders, including epilepsy, schizophrenia, and chronic pain [1].